Francisco Trust Under Agreemen Sells 26,340 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 26,340 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $2.43, for a total value of $64,006.20. Following the transaction, the insider directly owned 3,522,188 shares of the company’s stock, valued at approximately $8,558,916.84. This represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Trading Up 9.5%

NASDAQ DYAI opened at $1.06 on Wednesday. The business’s 50-day moving average price is $0.78 and its two-hundred day moving average price is $0.83. Dyadic International Inc. has a 12 month low of $0.65 and a 12 month high of $1.35. The firm has a market capitalization of $38.63 million, a PE ratio of -4.61 and a beta of 1.15. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. On average, analysts expect that Dyadic International Inc. will post 0.13 EPS for the current year.

Institutional Trading of Dyadic International

Large investors have recently bought and sold shares of the business. Bank of America Corp DE raised its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares in the last quarter. Marathon Capital Management acquired a new stake in Dyadic International during the third quarter worth approximately $41,000. Geode Capital Management LLC grew its stake in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the third quarter worth approximately $190,000. Finally, Apis Capital Advisors LLC acquired a new position in Dyadic International in the third quarter valued at approximately $1,817,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International News Summary

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations are continuing to validate its C1 platform and expand commercial potential, including work tied to Ebola preparedness, which may improve the long-term outlook for its technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: Recent quarterly results were mixed: revenue came in above expectations, but EPS missed estimates, keeping attention on whether Dyadic can convert its technology into sustained profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreement disclosed multiple recent stock sales, which may pressure sentiment because insider selling can raise concerns about near-term confidence in the shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dyadic International presently has a consensus rating of “Hold” and an average target price of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.